Table 2 Most common all-cause AEs reported in ≥5% of patients

From: Adjuvant icotinib for resected EGFR-mutated stage II–IIIA non-small-cell lung cancer (ICTAN, GASTO1002): a randomized comparison study

 

12-month icotinib (n = 84)

6-month icotinib (n = 84)

Observation (n = 83)

All-cause AEs

Any grade

Grade ≥ 3

Any grade

Grade ≥ 3

Any grade

Grade ≥ 3

Totala

65 (77.4)

7 (8.3)

62 (73.8)

5 (6.0)

35 (42.2)

2 (2.4)

Rash

31 (36.9)

3 (3.6)

32 (38.1)

2 (2.4)

1 (1.2)

0

Diarrhea

18 (21.4)

1 (1.2)

16 (19.0)

1 (1.2)

3 (3.6)

0

Raised aminotransferases

12 (14.3)

1 (1.2)

11 (13.1)

0

4 (4.8)

0

Leukopenia

4 (4.8)

1 (1.2)

5 (6.0)

0

7 (8.4)

1 (1.2)

Insomnia

6 (7.1)

1 (1.2)

4 (4.8)

1 (1.2)

7 (8.4)

0

Fatigue

5 (6.0)

0

4 (4.8)

1 (1.2)

3 (3.6)

1 (1.2)

Decreased appetite

4 (4.8)

0

5 (6.0)

0

2 (2.4)

0

Oral ulcers

5 (6.0)

0

3 (3.6)

0

1 (1.2)

0

  1. Data are presented as n (%). All AEs were reported in at least 5% of the patients in either trial group, according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0
  2. aTotal number of patients who had at least one AE; some patients had more than one AE
  3. Abbreviations: AEs, adverse events
Back to article page